Compare RYZ & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYZ | GLUE |
|---|---|---|
| Founded | 1842 | 2019 |
| Country | United States | United States |
| Employees | 4300 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2014 | 2021 |
| Metric | RYZ | GLUE |
|---|---|---|
| Price | $30.59 | $22.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 429.6K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | $75.79 | N/A |
| Revenue Next Year | $2.17 | $2.45 |
| P/E Ratio | ★ N/A | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $19.34 | $4.12 |
| 52 Week High | $31.09 | $25.77 |
| Indicator | RYZ | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 65.47 | 52.14 |
| Support Level | $23.49 | $17.35 |
| Resistance Level | $30.85 | $25.45 |
| Average True Range (ATR) | 1.08 | 1.54 |
| MACD | 0.38 | -0.25 |
| Stochastic Oscillator | 88.93 | 43.57 |
Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company has one operating and reportable segment, metals service centers. It derives substantially all of its sales from the processing and distribution of met. Geographically, the majority revenue is generated from the United States.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).